Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ConocoPhillips (COP) vs Viatris Inc (VTRS) Price & Performance

ConocoPhillipsTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

ConocoPhillips vs Viatris Inc — how do they compare? ConocoPhillips trades at $134.1 (market cap $161.21B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: ConocoPhillips is far larger — about 8× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and Viatris Inc for 57 Days on average.

COPVTRS
Market Cap
$161.21B$20.03B
Volume
6,058,40314,109,977
Sector
EnergyHealth
52-Week High
$141.22$18.27
52-Week Low
$85.66$9.74
Typical Hold Time
79 Days57 Days
Enterprise Value
$176.81B$32.15B
Dividend Yield
2.5%2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ConocoPhillips

ConocoPhillips (COP) trades at $134.19, up 3.35% today, with strong technical momentum and a bullish moving average signal. The company reported revenue of $58.94B in 2025 and net income of $7.99B, with recent earnings beats in Q1 and Q2 2026. A 20-year LNG supply deal with Venture Global and potential asset sales in Norway and the UK highlight strategic moves. Analyst consensus is strongly bullish with a $154.75 price target.

COP's outlook is supported by robust cash flow, a favorable energy market, and shareholder returns via dividends. Risks include geopolitical exposure in the Middle East, oil price volatility, and execution of asset sales. The stock offers growth potential from operational strength and LNG expansion, but investors must weigh geopolitical and commodity risks against upside from current valuations.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

COP
1% Buy99% Sell
Avg holding period · 79 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About ConocoPhillips

ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.

Read more on COP →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →